Cargando…

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes

BACKGROUND: Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on limited measurements, losing sight of the temporal pattern of these changes. METHODS: We conducted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pradenas, Edwards, Trinité, Benjamin, Urrea, Víctor, Marfil, Silvia, Ávila-Nieto, Carlos, Rodríguez de la Concepción, María Luisa, Tarrés-Freixas, Ferran, Pérez-Yanes, Silvia, Rovirosa, Carla, Ainsua-Enrich, Erola, Rodon, Jordi, Vergara-Alert, Júlia, Segalés, Joaquim, Guallar, Victor, Valencia, Alfonso, Izquierdo-Useros, Nuria, Paredes, Roger, Mateu, Lourdes, Chamorro, Anna, Massanella, Marta, Carrillo, Jorge, Clotet, Bonaventura, Blanco, Julià
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2021
Materias:	Clinical and Translational Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847406/ https://www.ncbi.nlm.nih.gov/pubmed/33554155 http://dx.doi.org/10.1016/j.medj.2021.01.005

Ejemplares similares

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection
por: Pradenas, Edwards, et al.
Publicado: (2022)

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
por: Trinité, Benjamin, et al.
Publicado: (2021)

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
por: Trinité, Benjamin, et al.
Publicado: (2021)

Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization
por: Pradenas, Edwards, et al.
Publicado: (2023)

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS‐CoV‐2 mRNA‐1237 vaccine in patients with solid tumors
por: Felip, Eudald, et al.
Publicado: (2022)

First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain
por: Fernández-Bastit, Leira, et al.
Publicado: (2021)

Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals
por: Pradenas, Edwards, et al.
Publicado: (2022)

Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals
por: Ainsua-Enrich, Erola, et al.
Publicado: (2022)

Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study
por: Abella, Eugenia, et al.
Publicado: (2022)

Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform—Analysis of Production and Immunogenicity
por: Ortiz, Raquel, et al.
Publicado: (2023)

Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice
por: Vidal, Enric, et al.
Publicado: (2021)

Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice
por: Tarrés-Freixas, Ferran, et al.
Publicado: (2022)

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
por: Rodon, Jordi, et al.
Publicado: (2021)

Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report
por: Massanella, Marta, et al.
Publicado: (2021)

Pigs are not susceptible to SARS‐CoV‐2 infection but are a model for viral immunogenicity studies
por: Vergara‐Alert, Júlia, et al.
Publicado: (2020)

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses
por: Tarrés-Freixas, Ferran, et al.
Publicado: (2023)

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities
por: Trigueros, Macedonia, et al.
Publicado: (2022)

Detection of SARS-CoV-2 in a cat owned by a COVID-19−affected patient in Spain
por: Segalés, Joaquim, et al.
Publicado: (2020)

Glucocorticoids’ treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients
por: Garcia-Cirera, Silvia, et al.
Publicado: (2022)

SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells
por: Perez-Zsolt, Daniel, et al.
Publicado: (2021)

Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells
por: Perez-Zsolt, Daniel, et al.
Publicado: (2022)

High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients
por: Rodríguez de la Concepción, María Luisa, et al.
Publicado: (2021)

Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
por: Brustolin, Marco, et al.
Publicado: (2021)

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity
por: Carrillo, Jorge, et al.
Publicado: (2021)

Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4(+) T-cell immune recovery
por: Gómez-Mora, Elisabet, et al.
Publicado: (2017)

Agreement and differential use of laboratory methods for the detection and quantification of SARS-CoV-2 in experimentally infected animals
por: Usai, Carla, et al.
Publicado: (2022)

The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis
por: Pérez-Yanes, Silvia, et al.
Publicado: (2022)

Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines
por: Aguilar-Gurrieri, Carmen, et al.
Publicado: (2023)

Susceptibility of Domestic Goat (Capra aegagrus hircus) to Experimental Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.351/Beta Variant
por: Fernández-Bastit, Leira, et al.
Publicado: (2022)

Prostaglandin E(2) Prevents Hyperosmolar-Induced Human Mast Cell Activation through Prostanoid Receptors EP(2) and EP(4)
por: Torres-Atencio, Ivonne, et al.
Publicado: (2014)

Myo1f, an Unconventional Long-Tailed Myosin, Is a New Partner for the Adaptor 3BP2 Involved in Mast Cell Migration
por: Navinés-Ferrer, Arnau, et al.
Publicado: (2019)

Enhanced antiviral immunity and dampened inflammation in llama lymph nodes upon MERS-CoV sensing: bridging innate and adaptive cellular immune responses in camelid reservoirs
por: Rodon, Jordi, et al.
Publicado: (2023)

Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis
por: Sachse, Martin, et al.
Publicado: (2022)

Remodeling the bladder tumor immune microenvironment by mycobacterial species with changes in their cell envelope composition
por: Senserrich, Jordi, et al.
Publicado: (2022)

Enhanced replication fitness of MERS-CoV clade B over clade A strains in camelids explains the dominance of clade B strains in the Arabian Peninsula
por: Te, Nigeer, et al.
Publicado: (2021)

Antiretroviral therapy suppressed participants with low CD4(+) T-cell counts segregate according to opposite immunological phenotypes
por: Pérez-Santiago, Josué, et al.
Publicado: (2016)

On the steps of cell-to-cell HIV transmission between CD4 T cells
por: Puigdomènech, Isabel, et al.
Publicado: (2009)

Animal models to study the neurological manifestations of the post-COVID-19 condition
por: Usai, Carla, et al.
Publicado: (2023)

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins
por: Díez, José María, et al.
Publicado: (2021)

Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4(+) T-cell immune recovery
por: Gómez-Mora, Elisabet, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gj1uf6ge2vh5hmu8rjbq6kt0ss